Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
PR Newswire•09/10/2026•08:00 ET
0
Key Highlights
- ➤25% of first qualifying PRV net proceeds allocated to CVR holders
- ➤$50 million aggregate cap limits total CVR payments
- ➤One stapled CVR declared per ATOS share, with October 19 record date
- ➤CVRs cover first qualifying PRV awarded by December 31, 2036
- ➤No Atossa product is FDA-approved, and no PRV has been awarded
Expert Statements
Steven C. Quay, Chairman, President and Chief Executive Officer of Atossa Therapeutics
“With the execution of the CVR Agreement, we have converted the commitment we announced in September into a contractual right for our shareholders”
Steven C. Quay, Chairman, President and Chief Executive Officer of Atossa Therapeutics
“If our development programs ultimately result in a qualifying priority review voucher, our shareholders will have a direct opportunity to participate in a meaningful portion of that potential value.”
Steven C. Quay, Chairman, President and Chief Executive Officer of Atossa Therapeutics
“At the same time, the structure preserves Atossa's flexibility to make development and capital allocation decisions that we believe are in the best interests of the Company and its shareholders.”
Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value PR Newswire
Board declares one stapled CVR for each share of Atossa common stock outstanding as of October 19, 2026 record date or issued thereafter
Get started
Create a free account to read the full story.